Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYRINGES: Enoxaparin plus cisplatin-based chemotherapy in advanced non-small cell lung cancer
2007-007696-16Phase 3Terminated
- Sponsor
- Thoracic Oncology Group of Australasia
- Start
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Thoracic Oncology Group of Australasia. Primary endpoint: Progression-free survival. Started Mar 2008; status: terminated.
02
Drugs
enoxaparin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-007696-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007696-16.